Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma

TECVAYLI^® and DARZALEX FASPRO^® combination led to a statistically significant progression-free survival and overall survival advantage compared to standard treatment after three years of follow-up